Trial Profile
Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sargramostim (Primary)
- Indications Pulmonary alveolar proteinosis
- Focus Therapeutic Use
- Acronyms FAMPAP
- 01 Mar 2016 New trial record
- 01 Mar 2016 New trial record